Drug shown to reduce new attacks/symptom progression in some patients
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.
Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of McGill University, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.
In one study, 732 patients with primary progressive MS were randomized on a 2:1 ratio to receive either ocrelizumab, a humanized monoclonal antibody that depletes CD20+ B cells, or a placebo.
The proportion of patients with 12-week confirmed disability progression was 39.3 per cent with the placebo versus 32.9 per cent with ocrelizumab. After 24 weeks, the proportion with confirmed disability progression was 35.7 per cent with placebo versus 29.6 per cent with ocrelizumab. By week 120, timed 25-foot walk worsened by 55.1 per cent for placebo versus 38.9 per cent for ocrelizumab. Patients given ocrelizumab were also found to have fewer new brain lesions and less brain volume loss than those given the placebo.
Researchers also tested ocrelizumab in two separate studies of patients with relapsing remitting MS, one a group of 821 and the other 835. In both studies, patients were randomized on a 1:1 ratio to receive either ocrelizumab or an already established treatment for relapsing MS: subcutaneous interferon-beta, injected three times weekly. Compared to the placebo, relapse rates in patients given ocrelizumab were 46-per-cent lower in one study and 47-per-cent lower in the other. Ocrelizumab was found to reduce the risk of disability progression after 12 weeks and 24 weeks, and reduced the number of new brain lesions.
The study noted that infusion-related reactions occurred in 34.3 per cent of ocrelizumab-treated patients. Serious infections were not more frequent with ocrelizumab compared to the interferon (1.3 versus 2.9 per cent respectively). Malignancies occurred in four ocrelizumab-treated patients and in two interferon-treated patients. Further observation is required to determine the long-term safety of ocrelizumab.
“The results in patients with relapsing remitting MS not only demonstrate very high efficacy against relapses, but also underscore the important emerging role of B cells of the immune system in the development of relapses,” says Bar-Or. “While the results in patients with primary progressive MS are more modest, they nonetheless represent the very first successful trial in such patients, a breakthrough as primary progressive MS now transitions from a previously untreatable condition to one that can be impacted by therapy. It is an important step forward in the field.”
These studies, funded by Roche, were published in the New England Journal of Medicine on Dec. 21, 2016.
MS in Canada
Canada has one of the world’s highest rates of MS – about 1,100 new cases each year. Some 50,000 Canadians have MS, and more than one-in-five patients are in Quebec. MS is one of the most common neurological diseases among young Canadians. Children as young as two can develop the disease. It typically strikes people in their prime years, between 15 and 40. Women are twice as likely as men to contract MS.
Learn more: Breakthrough in MS treatment
Receive an email update when we add a new MULTIPLE SCLEROSIS article.
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
- Albuquerque woman with multiple sclerosis loses disability benefits on December 8, 2018 at 7:12 pm
ALBUQUERQUE, N.M. – An Albuquerque woman diagnosed with multiple sclerosis is having her health benefits taken away. "I cried. I cried and I called my mom and was just like, ‘what do I do?’," said Tay... […]
- Multiple Sclerosis-Epidemiology Forecast to 2027 on December 7, 2018 at 9:39 am
The Multiple Sclerosis (MS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Multiple Sc... […]
- International Consensus on Timely Care for Multiple Sclerosis on December 7, 2018 at 8:25 am
Multiple sclerosis (MS) is a progressive neurological disease that requires timely management, and a panel of neurologists has developed an internationally applicable standard of care for timely manag... […]
- Global Multiple Sclerosis (MS) Market 2018 Key Players: Bayer Healthcare, Merck KGA, Teva Pharmaceutical, Biogen Idec. Limited, Biogen Idec. Limited. on December 6, 2018 at 2:59 am
WiseGuyReports.com adds “Multiple Sclerosis (MS) Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting 2027” reports tits database. Executive Summary DelveInsight’s ... […]
- Multiple Sclerosis Guidelines: Disease-Modifying Therapy on December 5, 2018 at 10:12 am
• Ascertain, incorporate, and review preferences in terms of safety, route of administration, lifestyle, cost, efficacy, common adverse effects (AEs), and tolerability in the choice of DMT. • Engage i... […]
- Medical News Today: Is the ketogenic diet good for multiple sclerosis? on December 5, 2018 at 8:00 am
Multiple sclerosis is a chronic condition that affects the nerves. The ketogenic diet, which is a low-carb, high-fat diet, may help protect the body against neurodegeneration, but more research is ... […]
- Multiple Sclerosis Drugs Market Outlook 2023: Top Companies, Trends And Future Prospects Details For Business Development on December 4, 2018 at 4:59 am
Further in the report, Global Multiple Sclerosis Drugs Market is examined for price, cost and revenue. In prolongation with this data sale price for various types, applications and region is also incl... […]
- Multiple Sclerosis-Market Insights Epidemiology and Market Forecast-2025 on December 4, 2018 at 1:11 am
The market revenue of Multiple Sclerosis is currently accounted by several approved therapies, some of which are dimethyl fumarate (Tecfidera; Biogen), Natalizumab (Tysabri; Biogen), Glatiramer acetat... […]
- Research on B Cells May Lead to Better Multiple Sclerosis Treatments on November 29, 2018 at 4:18 pm
Scientists say B cells can be beneficial, but too many can bring on MS symptoms. Share on Pinterest Researchers have been looking into the neurological effects of too many B cells in a person’s body. ... […]
via Bing News